According to the latest global monkeypox epidemic data released by the U.S. Centers for Disease Control and Prevention, as of 17:00 on June 24, 2022, the number of people infected with monkeypox virus (MPXV) has reached 4,106, compared with 2,525 seven days ago. The WHO believes that as further expand testing, more cases may be detected. With the progress of the epidemic, research on effective prevention and treatment strategies for monkeypox virus is also in full swing, and researchers are also required to carry out more research to screen monkeypox virus-specific vaccines and therapeutic drugs.
Monkeypox is a rare viral zoonotic disease and monkeypox virus is a close relative of smallpox virus. The clinical symptoms of patients are similar to those observed in smallpox patients in the past, but relatively less serious. Some monkeypox infected patients have systemic symptoms such as erythema or rash, but is not obvious and is localized to a certain extent. The monkeypox virus was detected on lab monkeys in 1958, and the first human monkeypox case was reported in the Republic of Congo in 1970. With the eradication of smallpox in 1980 and the subsequent cessation of vaccination against smallpox, monkeypox became the most serious orthopox virus. There are still sporadic cases of monkeypox in central and western Africa.
Monkeypox virus is a double-stranded DNA virus (≈197 kb), which has the ability to repair itself when it mutates, so it has some genetic stability, which also indicate the possibility of monkeypox virus mutation is very small, and its spread is hardly get stronger during a short period of time. Monkeypox virus is mainly prevalent in Central and West Africa, and has gradually evolved into two different genetic clades, among which the Central African clade has historically caused more serious diseases, with a fatality rate of up to 10.6%, and it can spread faster.
Studies have shown that due to the similarity of smallpox virus and monkeypox virus, cross-immunity can happen between these two, and in practice, the prevention efficiency of variola vaccine against monkeypox virus can reach 75-85%. At present, no specific vaccine has been developed against monkeypox, therefore the smallpox vaccine is still one of the most powerful weapons against monkeypox.
In response to the increasing spread of monkeypox virus globally, academia and industry are both responded quickly and accelerated research on products related to monkeypox virus diagnosis and treatment. As a global professional recombinant protein supplier, ABclonal has successfully developed the recombinant A29 protein expressed by the monkeypox virus A29L gene and the recombinant L1R protein expressed by the L1R gene, which has been designed according to the published monkeypox virus gene sequence to support monkeypox research. Other related recombinant protein products are also in development, so stay tuned!
Among them, A29 is the surface envelope protein of monkeypox virus, which is homologous to A27 of vaccinia virus and is widely conserved in poxviridae. Studies on vaccinia virus have found that the A27 protein plays a variety of roles in the virus life cycle, including binding to cell surface heparan sulfate, regulating membrane fusion, and mediating the transport of mature viruses to form enveloped viruses. L1R is a membrane protein that is homologous to vaccinia virus J1R. Studies have shown that vaccinia J1R is a membrane protein required for virus growth and plaque formation, and plays a role in the formation of immature virions.
New Released Product List
|RP01543||A29||Monkeypox virus||C-His||E. coli|
|RP01546||A29||Monkeypox virus||C-His||HEK293 cells|